
In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Catch up on coverage from the second day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Caulfield discusses his SPD 2024 lecture, "The Misinformation Crisis: How Did We Get Here and What Can We Do?"

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the first day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

In this episode, Albert Yan, MD, FAAP, FAAD, discusses his SPD 2024 session revolving around the helpful (or hindering?) role of artificial intelligence and chatbots in dermatology.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

In a milestone year for Dermatology Times, our Editorial Advisory Board reflects on advancements in their careers.

The conference aimed at providing pediatric dermatology clinicians with the latest in the specialty begins tomorrow in Toronto, Ontario.

Ahead of the SPD's Annual Meeting in Toronto, share with us: What do you hope to learn?

Preoperative pain and anticipated postoperative pain were found to predict postoperative pain in patients undergoing dermatologic surgery.

Lawrence Eichenfield, MD, provides insights into the clinical implications of topical ruxolitinib cream for atopic dermatitis and treatment patterns.

Explore dermatology's history and the journey through our publication's 45 years of covering an ever evolving specialty.

July 8th has been established as World Skin Health Day, with celebrations planned and anticipated on a global scale.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Some patients may be looking for alternatives to BPO, questioning its safety.